Invasive lobular carcinoma is the second most common type of breast cancer, yet there is still much to learn about what makes this disease biologically distinct. In this episode, we sit down with Associate Professor Amy McCart Reed to explore the molecular underpinnings of invasive lobular carcinoma. Associate Professor McCart Reed discusses what researchers are learning about the biology of invasive lobular carcinoma, recent discoveries shaping our understanding of the disease, and how this research could ultimately lead to more personalised treatments and better outcomes for people living with a lobular diagnosis.(2:01) What have been some of the biggest discoveries in recent years that are changing the way researchers think about this subtype of breast cancer?(02:57) Are we aiming to move more towards personalised treatment for breast cancer?(03:27) What research still needs to happen in this space?(05:17) What is the key message that you'd like researchers and clinicians to take away from this episode?Tune in for a deep dive into this important research.Donate to support live-saving research.Like this episode? ⁠⁠Follow Breast Cancer Trials on Social Media: Instagram:⁠ ⁠@breastcancertrialsFacebook:⁠ ⁠Breast Cancer TrialsLinkedIn: ⁠⁠Breast Cancer TrialsX: ⁠⁠@BCTrialsANZGuest: Molecular Biologist, Associate Professor Amy McCart Reed.Thank you for listening! If you found this episode valuable, please share it with your loved ones and help spread awareness about the importance of clinical trials research.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related